CoChat

Pharmacovigilance study of GLP-1 receptor agonists for metabolic and nutritional adverse events

Open access

The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.

Abstract

Aims: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are employed extensively in the management of type 2 diabetes and obesity. However, there is a paucity of real-world data on their safety and tolerability for metabolic and nutritional adverse events in large sample populations. This study aimed to analyse the metabolic and nutritional safety signatures of different GLP-1 RAs by exploring the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS). Methods: AEs data were extracted from the FDA Adverse Event Reporting System database for each GLP-1 RA from the time of its launch until the second quarter of 2023. The reported odds ratio (ROR), proportional reporting ratio (PRR), Empirical Bayesian Geometric Mean and Bayesian Confidence Propagation Neural Network were employed to identify AE signals. Results: A system organ class of metabolism and nutrition disorders was employed to filter AE reports, resulting in the identification of 10,450 reports for exenatide, 2,860 reports for liraglutide, 240 reports for albiglutide, 4,847 reports for dulaglutide, 2,905 reports for semaglutide, 1,089 reports for tirzepatide, and 13 reports for lixisenatide. Semaglutide (ROR, 3.34; 95%CI, 3.22), liraglutide (ROR, 2.78; 95%CI, 2.69), and exenatide (ROR, 2.15; 95%CI, 2.11) were associated with metabolism and nutrition disorders. The number of AE signals detected were as follows: albiglutide (n = 1), lixisenatide (n = 2), tirzepatide (n = 11), exenatide (n = 12), liraglutide (n = 16), semaglutide (n = 20), dulaglutide (n = 22). Dehydration was the most frequent AE contributing to serious outcomes for liraglutide (n = 318, 23.93%), dulaglutide (n = 434, 20.90%), semaglutide (n = 370, 25.10%) and tirzepatide (n = 70, 32.86%). The time to onset (TTO) of AE was statistically different between exenatide and the other GLP-1 RAs ( p < 0.001), and the Weibull parameters for dehydration for liraglutide, dulaglutide, and semaglutide analyses all showed an early failure-type profile. Conclusion: Our study suggests that exenatide, liraglutide, and semaglutide are more susceptible to metabolic and nutritional AEs than other GLP-1 RAs. Liraglutide, dulaglutide, semaglutide, and tirzepaptide’s potential to induce dehydration, necessitates special attention. Despite certain deficiencies, GLP-1 RAs have considerable potential for the treatment of eating disorders.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fphar.2024.1416985

Cites

59 of 59 references verified0 citation errors · 0 not checkable

Statistics

Figures

FIGURE 1 Flow chart of data extraction and analysis. A detailed description of the flow chart for data extraction and analysis of adverse events for GLP-1 RAs for metabolism and nutrition disorders in the United States Food and Drug Administration Adverse Event Reporting System (FAERS).
FIGURE 1 Flow chart of data extraction and analysis. A detailed description of the flow chart for data extraction and analysis of adverse events for GLP-1 RAs for metabolism and nutrition disorders in the United States Food and Drug Administration Adverse Event Reporting System (FAERS).CC BY · PubMed Central
FIGURE 2 Results of disproportionate analysis of AEs associated with metabolism and nutrition of seven GLP-1 RAs at the PT level. (A) ROR 95%CI, PRR 95%CI, EBGM05, IC025 for exenatide metabolism and nutrition-associated AEs. (B) ROR 95%CI, PRR 95%CI, EBGM05, IC025 for liraglutide metabolism and nutrition-associated AEs. (C) ROR 95%CI, PRR 95%CI, EBGM05, IC025 for dulaglutide metabolism and nutrition-associated AEs. (D) ROR 95%CI, PRR 95%CI, EBGM05, IC025 for semaglutide metabolism and nutrition-associated AEs. (E) ROR 95%CI, PRR 95%CI, EBGM05, IC025 for tirzepatide metabolism and nutrition-associated AEs. (F) ROR 95%CI, PRR 95%CI, EBGM05, IC025 for albiglutide metabolism and nutrition-associated AEs. (G) ROR 95%CI, PRR 95%CI, EBGM05, IC025 for lixisenatide metabolism and nutrition-associated AEs. (H) Overlap relationship between the positive signals of five GLP-1RAs at the pt levels. GLP-1RA, glucagon-like peptide-1 receptor agonist; AE, adverse event; PT, preferred term; ROR, reporting odds ratio; PRR, proportional reporting rate; EBGM05, lower one-sided 95% confidence limit (95% CI) of the empirical Bayes geometric mean; IC025, lower bound of the information component for the Bayesian confidence propagation neural network.
FIGURE 2 Results of disproportionate analysis of AEs associated with metabolism and nutrition of seven GLP-1 RAs at the PT level. (A) ROR 95%CI, PRR 95%CI, EBGM05, IC025 for exenatide metabolism and nutrition-associated AEs. (B) ROR 95%CI, PRR 95%CI, EBGM05, IC025 for liraglutide metabolism and nutrition-associated AEs. (C) ROR 95%CI, PRR 95%CI, EBGM05, IC025 for dulaglutide metabolism and nutrition-associated AEs. (D) ROR 95%CI, PRR 95%CI, EBGM05, IC025 for semaglutide metabolism and nutrition-associated AEs. (E) ROR 95%CI, PRR 95%CI, EBGM05, IC025 for tirzepatide metabolism and nutrition-associated AEs. (F) ROR 95%CI, PRR 95%CI, EBGM05, IC025 for albiglutide metabolism and nutrition-associated AEs. (G) ROR 95%CI, PRR 95%CI, EBGM05, IC025 for lixisenatide metabolism and nutrition-associated AEs. (H) Overlap relationship between the positive signals of five GLP-1RAs at the pt levels. GLP-1RA, glucagon-like peptide-1 receptor agonist; AE, adverse event; PT, preferred term; ROR, reporting odds ratio; PRR, proportional reporting rate; EBGM05, lower one-sided 95% confidence limit (95% CI) of the empirical Bayes geometric mean; IC025, lower bound of the information component for the Bayesian confidence propagation neural network.CC BY · PubMed Central
FIGURE 3 Cumulative distribution curves demonstrating the onset time of glucagon-like peptide-1 receptor agonist (GLP-1 RA)-related metabolic and nutritional adverse events after treatment with different GLP-1 RAs.
FIGURE 3 Cumulative distribution curves demonstrating the onset time of glucagon-like peptide-1 receptor agonist (GLP-1 RA)-related metabolic and nutritional adverse events after treatment with different GLP-1 RAs.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

6 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 53

Metadata

Authors
He, L., Li, Q., Yang, Y., Li, J., Luo, W., Huang, Y., & Zhong, X.
Affiliations
Southwest Medical University (CN)
Corresponding author
  • Huang, Yilan
  • Zhong, Xiaoyan
Venue
Frontiers in Pharmacology
Published
2024-07-08
Volume
15
Pages
1416985-1416985
ISSN
1663-9812 (ISSN-L)
OpenAlex
W4400430779
Cited by
40
References
59
Citations by year
2026: 19 · 2025: 20 · 2024: 1
FWCI
9.47
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Pharmacology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Keywords
GLP-1 receptor agonists, adverse event signals, metabolic side effects, dehydration, liraglutide, semaglutide, dulaglutide, exenatide, tirzepatide, albiglutide, lixisenatide, type 2 diabetes, obesity, drug safety, FDA Adverse Event Reporting System, pharmacovigilance

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.